From September, Dr Baselga combines the scientific management of the Vall d’Hebron Institute of Oncology (VHIO) with his new appointment at the Hematology & Medical Oncology Division at the Cancer Center of the Massachusetts General Hospital at Harvard Medical School in Boston.
Related Posts
´We can. I can´: Today 04 February is World Cancer Day
Today´s World Cancer Day (WCD) marks the launch of a new three-year campaign led by the Union for International Cancer…
04 Feb 2016
VHIO and the Fritz Bender Foundation present latest advances in individualized cancer treatments
17th Fritz Bender Foundation International Symposium: Progress Towards Individualized Cancer Treatments, 07 – 09 November, 2013 To be inaugurated today,…
12 Nov 2013
Gastrointestinal Cancers Symposium 2015: findings from a phase III study indicate a possible new treatment strategy for patients with advanced colorectal cancer
Results from an international phase III study of patients with advanced colorectal cancer, a disease which is especially difficult to…
16 Jan 2015
ICREA: promoting latest discovery to better elucidate cancer evolution and tumor heterogeneity
Considering cancer from an evolutionary perspective in order to better understand its vast complexity and clonal dynamics is undoubtedly opening…
09 Mar 2017
Latest VHIO research explores therapeutic combinations to revert ER+ breast cancer resistance to anticancer agents
VHIO´s Violeta Serra, Principal Investigator of our Experimental Therapeutics Group has co-authored research exploring ER-positive breast cancer resistance to therapies…
15 Apr 2016
Backing breast cancer research of excellence: the Conquer Cancer Foundation awards VHIO´s Cristina Cruz
Celebrated last week during the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), Cristina Cruz receives a…
04 Jun 2015
2012 Fero Foundation Grant to support the study of genetic alterations in advanced colon cancer towards personalized medicine
21 May 2012, Barcelona – Héctor G. Palmer, Principal Investigator of the Stem Cells and Cancer Group at the Vall…
24 May 2012
Last month´s two-day exchange and debate on reversing cancer drug resistance: the Biocat and Obra Social “la Caixa” B-Debate 07 – 08 April 2016
Co-Organized by the Catalan Institute of Oncology (ICO), the Program Against Therapeutic Resistance (ProCURE), and Vall d´Hebron Institute of Oncology…
18 May 2016
VHIO scientists and AICR Atlas trekking team to raise funds for cancer research: donate today
Comprised of AICR (now rebranded as Worldwide Cancer Research) donors, supporters, staff and AICR grant holders, some 15 individuals, including VHIO´s…
03 Mar 2014
Cancer Core Europe´s 2017 Summer School in Translational Cancer Research returns to Portugal to promote bench-bedside translational and multidisciplinary interaction
Initially launched back in 2011 by the EurocanPlatform, the annual Summer School in Translational Cancer Research is organized under the…
25 May 2017
Genomic alterations decoded for the first time in one of the most serious hereditary cancers
VHIO scientists discover a common factor among different tumours in a patient with Li-Fraumeni syndrome further to whole-genome sequencing This…
07 Oct 2013
The ”la Caixa” Banking Foundation pays homage to medical researchers
Source: the ”la Caixa” Banking Foundation Josep Baselga, María Blasco, Valentí Fuster, Maite Mendioroz, Eduard Gratacós, Bonaventura Clotet and Pedro…
06 Sep 2017
Genomic study leads to classification of fibroepithelial breast cancer and predicts tumor cell behavior
The study, led by VHIO, is the first to use gene expression to classify fibroepithelial tumors Genomic discovery reveals decisively…
18 Mar 2015
Pharmacological drugs under investigation show effect on tumor-initiating cells
The group led by Dr Joan Seoane, ICREA Research Professor at the VHIO, has carried out the research in glioma, the most common malignant brain tumor. The study published describes how to identify cells with characteristics of stem cells in the interior of the glioma. These cells, known as Glioma initiating cells (GICs), are responsible for initiating the glioma and also for it reappearing after surgical removal.
13 Dec 2010
Latest research led by VHIO: cutting edge ´omics´ predict breast cancer patients´ response to chemotherapy
Latest research led by VHIO, recently published in Clinical Cancer Research, validates the predictive power of a novel genomic technology…
15 Jul 2015
